MedTrace Logo

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

NCT02932436 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2021-04-19

No results posted yet for this study

Summary

The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2
  • Diastolic Dysfunction

Interventions

DRUG

Empagliflozin

10 mg per os daily for 12 weeks

DRUG

Placebo

amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Philipp Wild, MD, MSc · Johannes Gutenberg University Mainz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-10
Primary Completion
2020-06-15
Completion
2020-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02932436 on ClinicalTrials.gov